Gilead Sciences 1Q

1Q Revenues: $2.1 billion (+36%)

1Q Earnings: $855 million (+45%)

Comments: Atripla HIV treatment sales were $693 million (+36%) while Truvada sales were $658 million (+11%). Sales of pulmonary arterial hypertension drug Letairis were up 40% to $55.5 million. Royalties, contract and other revenues were $298 million, up from $83 million in 1Q09, driven mainly by higher Tamiflu royalties ($246.3 million to $33.2 million) from Roche.